Two red flag signs that could mean you have Britain's deadliest cancer
NHS launches pilot scheme for GPs to scour their medical records and contact patients who have two "red flag" signs of pancreatic cancer
GPs will scour their medical records for patients who have two red flag signs that they may have pancreatic cancer.
Pancreatic cancer is the UK's tenth most common cancer but it has the lowest five-year survival rate of any common cancer. Most people with pancreatic cancer die within a year of diagnosis and only 7% survive five years or more. That is because symptoms are vague and most people are diagnosed only once the cancer is widespread. Now an NHS pilot in England will see 300 participating GP practices search their medical records of patients who are aged over 60.
Doctors will contact patients if they have the two red flag signs - which are a recent diagnosis of diabetes and sudden weight loss.
Professor Peter Johnson, NHS National Clinical Director for Cancer: 'Pancreatic cancer is responsible for so many deaths because patients don't usually notice symptoms until the cancer is at an advanced stage, which is why we need to find new ways to pick it up. Through initiatives like this and the upcoming 10 Year Health Plan the NHS is determined to go a step further – not just treat people at an advanced stage but to go out into communities and seek people out who might be unwell without any symptoms so we can provide people with the most effective treatment.
'The NHS is seeing and treating more people with cancer than ever, and early diagnosis is key to ensure patients have the best chance of receiving effective treatment. If your GP practice identifies you as at risk of pancreatic cancer, I urge you to come forward for testing as soon as possible.'
Around 10,500 people are diagnosed with pancreatic cancer in the UK each year and it kills around 10,000 people annually.
Early Warning Signs
Around half of people diagnosed with pancreatic cancer have been diagnosed with diabetes recently. The NHS pilot will focus on this and a record of sudden recent weight loss in the over 60s age group who are at greater risk. Other possible symptoms of pancreatic cancer include:
Jaundice (yellowing of the skin and eyes)
Abdominal or back pain
Changes in bowel habits (pale or greasy stools, dark urine)
Itchy skin
Loss of appetite
Nausea
Fatigue
Dr Agnieszka Lemanska, expert at the University of Surrey and Lead Evaluator for the pilot, said: 'Unexplained weight loss can be an early warning sign, especially in people with diabetes, but it is not always picked up. We are creating tools which will help us use GP records more effectively to identify people through simple body weight and blood glucose control measurements.
"This could be key to spotting pancreatic cancer early. The success of this pilot relies on high quality and complete GP data, and with this scheme we are working to improve monitoring of body weight and blood glucose control.'
The pancreas is a large gland that produces digestive juices and hormones. Surgical removal is the only potentially curative treatment but only a small percentage of patients are eligible because the organ is so hard to reach.
GP teams already know the signs to look for, but this new scheme provides almost £2m in targeted funding to help practices reach out to those most at risk.
Alfie Bailey-Bearfield, spokesman for Pancreatic Cancer UK, said: 'Diagnosing more people with pancreatic cancer earlier, when the disease is most treatable, would make the single biggest difference to improving survival, so we are delighted to see significant further investment from NHS England towards that incredibly important goal.
'We're proud to have been involved in shaping this new case finding pilot, which will support GPs to proactively find people with pancreatic cancer among one of largest groups known to be at increased risk: those aged over 60, with new onset diabetes who have recently lost weight without trying to do so. Many of the people who are referred for a CT scan during the pilot will not have pancreatic cancer, but for those that do, the impact could be lifesaving."
Family doctors taking part in the new pilot will then contact patients and send them for urgent blood tests and CT scans to rule out cancer. If successful, it will be expanded nationwide.
Health Minister Karin Smyth, herself a skin cancer survivor, said: "As someone who has faced cancer personally, I know all too well the fear that comes with a diagnosis and the precious value of catching it early. This targeted approach to identify people at risk of one of the most lethal cancers could give more people a fighting chance and spare the heartbreak of countless families.
"Through our Plan for Change, we are utilising the latest technology and techniques to improve cancer outcomes and transform care to give more families hope in the face of this devastating disease."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
33 minutes ago
- The Independent
Weight loss pill shows promise in new trial
A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
South Wales Guardian
an hour ago
- South Wales Guardian
Weight loss pill shows promise in new trial
An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
Leader Live
an hour ago
- Leader Live
Weight loss pill shows promise in new trial
An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
